可溶性CD163在急性冠脉综合征患者血清中的表达及意义

Clinical significance of soluble CD163 in acute coronary syndrome patients

目的探讨可溶性CD163(soluble CD163,s CD163)在急性冠脉综合征患者血清中的水平及临床意义。方法以2013年2月至2014年12月在本院就诊的672例急性冠脉综合征患者和305例同期接受体检的健康成年人作为研究对象,采用酶联免疫吸附法检测两组研究对象血清中s CD163的水平,并进行相关统计学分析。结果急性冠脉综合征患者血清中s CD163水平在入院后24 h内、72 h及30 d后均显著高于健康对照组(P<0.05),急性冠脉综合征患者血清中s CD163的水平与患者的Gensini评分存在显著相关性,Gensini评分越高的患者血清中s CD163的水平越高(P<0.05);ROC曲线分析表明:以651.5 ng/m L为界值,s CD163诊断急性冠脉综合征的灵敏度为85.40%,特异度为91.52%,ROC曲线下面积为0.931 3。结论 s CD163在急性冠脉综合征患者血清中的水平明显增高,有可能成为诊断急性冠脉综合征的新指标。

Objective To investigate the expression of serum soluble CD163 （ sCD163 ） in the patients with acute coronary syndrome （ACS） and its clinical significance. Methods A total of 672 patients with ACS admitted to the hospital from February 2013 to December 2014 were enrolled, and 305 healthy volunteers were taken as controls. Blood samples were obtained in 24 h, 72 h, and 30 d after ACS. ELISA was used to determine the expression of sCD163. The correlation between sCD163 level and Gensini score was evaluated. Results The patients with ACS showed higher expression of sCD163 than the controls in 24 h, 72 h and 30 d after ACS （P 〈 0.05）. Furthermore, serum sCD163 level was positively related with the Gensini score （P 〈0.05）. Based on the ROC curve, the boundary value of sCD163 was 651.5 ng/mL. The sensitivity and specificity of sCD163 in diagnosis of ACS were 85.40% and 91.52% , respectively. The area under the ROC curve was 0.931 3. Conclusion Increased serum sCD163 level may be an early predictor of outcome in patients with ACS.